Diaryl urea derivative sorafenib [1], the first oral multikinase inhibitor targeted Raf and receptor tyrosine kinases (RTKs), has been applied for the treatment of advanced renal cell carcinoma (RCC) [2], unresectable hepatocellular carcinoma (HCC) [3], and differentiated thyroid carcinoma (DTC) [4]. This evidence concerns the gene NTRK1 and hepatocellular carcinoma.